| Literature DB >> 21908464 |
M Cristina Magli1, Markus Montag, Maria Köster, Luigi Muzi, Joep Geraedts, John Collins, Veerle Goossens, Alan H Handyside, Joyce Harper, Sjoerd Repping, Andreas Schmutzler, Katerina Vesela, Luca Gianaroli.
Abstract
BACKGROUND: The purpose of this study was to assess the technical aspects related to polar body (PB) biopsy, which might have an influence on the results of the microarray comparative genomic hybridization analysis. Furthermore, a comparison was made between two biopsy methods (mechanical and laser).Entities:
Mesh:
Substances:
Year: 2011 PMID: 21908464 PMCID: PMC3196879 DOI: 10.1093/humrep/der295
Source DB: PubMed Journal: Hum Reprod ISSN: 0268-1161 Impact factor: 6.918
Time frame for a cycle with PB biopsy and array CGH.
| Bonn | Bologna | |||
|---|---|---|---|---|
| Oocyte retrieval | Day 0 | Approx. 13:00 | Day 0 | Approx. 8:00 |
| ICSI | Day 0 | 20:30–21:00 | Day 0 | 11:00–11:30 |
| Biopsy/transfer to PCR tubes | Day 1 | 5:20–5:40 | Day 0 | 20:00–20:30a |
| Amplification | Day 1 | 5:45–9:00 | Day 0 | 20:40–23:45 |
| Labelling/concentration | Day 1 | 9:00–12:00 | Day 0–Day 1 | 23:45–03:25 |
| Hybridization | Day 1 | 12:00–15:15 | Day 1 | 3:25–6:30 |
| Washing: | Day 1 | 15:15–15:55 | Day 1 | 6:30–7:05 |
| Scanning/diagnosisb | Day 1 | 16:05–17:05 | Day 1 | 7:05–8:05 |
| Oocyte selection | Day 1 | 17:05 | Day 1 | 8:10 |
aThis is the time adopted for the last 65 consecutive biopsies in Bologna. For the previous oocytes, biopsy was performed 6–7 h after ICSI.
bTime frame for scan and diagnosis for six oocytes corresponding to 12 PBs. Additional six oocytes will require another 70 min.
Figure 1The presence of a faint but clearly identifiable strand connecting PB2 to the oolemma. The biopsy was performed ∼9 h after ICSI.
Results of PB amplification and diagnosis.
| Total | Bonn | Bologna | ||
|---|---|---|---|---|
| Number of cycles (patients) | 42 (41) | 20 (19) | 22 (22) | — |
| Age (mean ± SD), years | 40.0 ± 2.9 | 39.9 ± 3.3 | 40.2 ± 2.6 | — |
| Number of biopsied oocytes (mean ± SD) | 226 (5.4 ± 3.3) | 126 (6.3 ± 4.1) | 100 (4.5 ± 2.1) | — |
| Number of biopsied PBs | 452 | 252 | 200 | — |
| Number of amplified PBs (%) | 428 (95) | 245 (97) | 183 (92) | <0.025 |
| Number of diagnosed PBs | 419 | 237 | 182 | |
| (%/biopsied) | (93) | (94) | (91) | |
| (%/amplified) | (98) | (97) | (99) | |
| Number of biopsied PB1 | 226 | 126 | 100 | — |
| Number of amplified PB1 (%) | 214 (95) | 120 (95) | 94 (94) | — |
| Number of diagnosed PB1 | 212 | 118 | 94 | |
| (%/diagnosed) | (94) | (94) | (94) | |
| (%/amplified) | (99) | (98) | (100) | |
| Number of biopsied PB2 | 226 | 126 | 100 | — |
| Number of amplified PB2 (%) | 214 (95) | 125 (99) | 89 (89) | <0.005 |
| Number of diagnosed PB2 | 207 | 119 | 88 | |
| (%/biopsied) | (92) | (94) | (88) | |
| (%/amplified) | (97) | (95) | (99) |